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Introduction {#ajt13598-sec-0002}
============

BK polyomavirus (BKPyV) is a small nonenveloped double‐stranded DNA virus and one of, by now, at least 13 human polyomaviruses [1](#ajt13598-bib-0001){ref-type="ref"}, [2](#ajt13598-bib-0002){ref-type="ref"}. Specific antibody surveys indicate that BKPyV infects 80--95% of the human population, mostly during childhood and without specific symptoms or signs [3](#ajt13598-bib-0003){ref-type="ref"}, [4](#ajt13598-bib-0004){ref-type="ref"}, [5](#ajt13598-bib-0005){ref-type="ref"}. BKPyV then persists in the renourinary tract, as demonstrated by asymptomatic shedding into the urine [4](#ajt13598-bib-0004){ref-type="ref"}, [6](#ajt13598-bib-0006){ref-type="ref"}, [7](#ajt13598-bib-0007){ref-type="ref"}. Disease manifestations arise almost exclusively in persons with altered immune functions and appear to involve cofactors linked to specific clinical settings [8](#ajt13598-bib-0008){ref-type="ref"}. Consequently, polyomavirus‐associated nephropathy (PyVAN) occurs in 1--15% of kidney transplant recipients (KTRs), whereas polyomavirus‐associated hemorrhagic cystitis (PyVHC) affects 5--20% of allogeneic hematopoietic stem cell transplant patients [2](#ajt13598-bib-0002){ref-type="ref"}, [9](#ajt13598-bib-0009){ref-type="ref"}, [10](#ajt13598-bib-0010){ref-type="ref"}. PyVAN and PyVHC have a significant impact on morbidity and graft and patient survival [11](#ajt13598-bib-0011){ref-type="ref"}, [12](#ajt13598-bib-0012){ref-type="ref"}, [13](#ajt13598-bib-0013){ref-type="ref"}, [14](#ajt13598-bib-0014){ref-type="ref"}, [15](#ajt13598-bib-0015){ref-type="ref"}, [16](#ajt13598-bib-0016){ref-type="ref"}, [17](#ajt13598-bib-0017){ref-type="ref"}, [18](#ajt13598-bib-0018){ref-type="ref"}. Despite considerable virologic research [19](#ajt13598-bib-0019){ref-type="ref"}, [20](#ajt13598-bib-0020){ref-type="ref"}, [21](#ajt13598-bib-0021){ref-type="ref"}, [22](#ajt13598-bib-0022){ref-type="ref"}, [23](#ajt13598-bib-0023){ref-type="ref"}, randomized clinical studies either are lacking or failed to demonstrate effective antiviral therapies [24](#ajt13598-bib-0024){ref-type="ref"}. In kidney transplantation (KT), high‐level BKPyV viruria and viremia have been identified as markers of progression to PyVAN [25](#ajt13598-bib-0025){ref-type="ref"}, thus current management strategies recommend screening KTRs for viremia followed by reducing immunosuppression [26](#ajt13598-bib-0026){ref-type="ref"}, [27](#ajt13598-bib-0027){ref-type="ref"}, [28](#ajt13598-bib-0028){ref-type="ref"}. In prospective observational studies, this preemptive intervention has been successful, as shown by clearance of viremia and PyVAN in 80--100% of cases, with a low risk of subsequent acute rejection in 0--14% of patients [29](#ajt13598-bib-0029){ref-type="ref"}, [30](#ajt13598-bib-0030){ref-type="ref"}, [31](#ajt13598-bib-0031){ref-type="ref"}, [32](#ajt13598-bib-0032){ref-type="ref"}, [33](#ajt13598-bib-0033){ref-type="ref"}. BKPyV viremia clearance has been paralleled by increasing BKPyV‐specific T cell responses in peripheral blood [30](#ajt13598-bib-0030){ref-type="ref"}, [34](#ajt13598-bib-0034){ref-type="ref"}, [35](#ajt13598-bib-0035){ref-type="ref"}, [36](#ajt13598-bib-0036){ref-type="ref"}. Because BKPyV‐specific T cell responses are ≈50‐ to 100‐fold lower than those to cytomegalovirus, these assays have not readily entered clinical practice. Moreover, the risk factors for BKPyV replication and nephropathy vary in different KT studies and include steroid pulses for acute rejection, maintenance immunosuppression such as tacrolimus--mycophenolate versus cyclosporine--mycophenolate, older age of recipients, male sex and a higher number of HLA mismatches [37](#ajt13598-bib-0037){ref-type="ref"}, [38](#ajt13598-bib-0038){ref-type="ref"}, [39](#ajt13598-bib-0039){ref-type="ref"}, [40](#ajt13598-bib-0040){ref-type="ref"}, [41](#ajt13598-bib-0041){ref-type="ref"}, [42](#ajt13598-bib-0042){ref-type="ref"}, [43](#ajt13598-bib-0043){ref-type="ref"}, [44](#ajt13598-bib-0044){ref-type="ref"}, [45](#ajt13598-bib-0045){ref-type="ref"}. According to the recent Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients report, these risk factors are present in a substantial number of KT patients [46](#ajt13598-bib-0046){ref-type="ref"}. Moreover, organs from BKPyV IgG--positive donors for recipients with low or undetectable antibodies may face an increased risk [34](#ajt13598-bib-0034){ref-type="ref"}, [35](#ajt13598-bib-0035){ref-type="ref"}, [36](#ajt13598-bib-0036){ref-type="ref"}, [37](#ajt13598-bib-0037){ref-type="ref"}, [38](#ajt13598-bib-0038){ref-type="ref"}, [39](#ajt13598-bib-0039){ref-type="ref"}, [40](#ajt13598-bib-0040){ref-type="ref"}, [41](#ajt13598-bib-0041){ref-type="ref"}, [42](#ajt13598-bib-0042){ref-type="ref"}, [43](#ajt13598-bib-0043){ref-type="ref"}, [44](#ajt13598-bib-0044){ref-type="ref"}, [45](#ajt13598-bib-0045){ref-type="ref"}, [46](#ajt13598-bib-0046){ref-type="ref"}, [47](#ajt13598-bib-0047){ref-type="ref"}, [48](#ajt13598-bib-0048){ref-type="ref"}.

We and others investigated cellular immune responses to overlapping peptide pools encoded in the early viral gene region (EVGR) or the late viral gene region (LVGR) of the BKPyV DNA genome [30](#ajt13598-bib-0030){ref-type="ref"}, [35](#ajt13598-bib-0035){ref-type="ref"}, [36](#ajt13598-bib-0036){ref-type="ref"}, [49](#ajt13598-bib-0049){ref-type="ref"}, [50](#ajt13598-bib-0050){ref-type="ref"}. T cell responses to the LVGR‐encoded capsid viral protein VP1 were generally more pronounced than those to EVGR‐encoded viral proteins [30](#ajt13598-bib-0030){ref-type="ref"}, [35](#ajt13598-bib-0035){ref-type="ref"}, [49](#ajt13598-bib-0049){ref-type="ref"}. Interferon γ (IFN‐γ) responses were largely derived from CD4^+^ T cells and, to a lesser extent, from CD8^+^ T cells [30](#ajt13598-bib-0030){ref-type="ref"}, [35](#ajt13598-bib-0035){ref-type="ref"}, [51](#ajt13598-bib-0051){ref-type="ref"}, [52](#ajt13598-bib-0052){ref-type="ref"}, [53](#ajt13598-bib-0053){ref-type="ref"}. Because most of these studies used overlapping 15mer peptide pools (15mP), the contribution of individual CD8^+^ T cell--restricted epitopes to these responses is largely undefined. With few exceptions, HLA‐restricted T cell responses to BKPyV are mostly reported from HLA‐A\*02 individuals [51](#ajt13598-bib-0051){ref-type="ref"}, [54](#ajt13598-bib-0054){ref-type="ref"}, [55](#ajt13598-bib-0055){ref-type="ref"}, [56](#ajt13598-bib-0056){ref-type="ref"}. To better characterize BKPyV‐specific CD8^+^ T cell epitopes, a bioinformatics approach was chosen to predict 9mer epitopes encoded in BKPyV EVGR and presented by 14 common HLA types in Europe and North America for experimental testing in healthy adult individuals and pediatric KTRs.

Materials and Methods {#ajt13598-sec-0003}
=====================

Healthy participants {#ajt13598-sec-0004}
--------------------

Peripheral blood mononuclear cells (PBMCs) were prepared from 42 healthy individual (HIs), consisting of 34 blood donors from the Swiss Red Cross blood donation center in Basel, Switzerland, and from eight other healthy volunteers (Table S1). HLA types were determined with fee‐for‐service by the Transplantation Immunology Laboratory (Basel). Participants gave written informed consent for the protocol (IRB 267/06), which was approved by the local institutional review board (IRB).

Pediatric KTRs {#ajt13598-sec-0005}
--------------

A total of 118 consecutive pediatric KTRs were referred to the Genova Pediatric Kidney Transplant Program between March 2003 and November 2012. Three were aged \>21 years but were still included in the cohort because they were initially received care as children for their end‐stage renal disease the Nephrology Unit, IRCCS, Genova, Italy. Cryopreserved PBMCs were analyzed from 19 KTRs protected (i.e. without BKPyV viremia) or recovering from BKPyV replication (Table S2). The study was approved by the local IRB (867/2014).

BKPyV IgG enzyme‐linked immunosorbent assay {#ajt13598-sec-0006}
-------------------------------------------

BKPyV IgG serology was performed using BKPyV VP1‐derived virus‐like particles, as described previously [4](#ajt13598-bib-0004){ref-type="ref"}, [57](#ajt13598-bib-0057){ref-type="ref"}, [58](#ajt13598-bib-0058){ref-type="ref"}.

In silico epitope prediction {#ajt13598-sec-0007}
----------------------------

The Syfpeithi database [59](#ajt13598-bib-0059){ref-type="ref"} provided information about HLA class I peptide binding affinity [60](#ajt13598-bib-0060){ref-type="ref"}, whereas the Immune Epitope Database and Analysis Resource [61](#ajt13598-bib-0061){ref-type="ref"} provided a multiparametric prediction based on proteasomal cleavage, TAP transport and HLA class I peptide binding [62](#ajt13598-bib-0062){ref-type="ref"}. The predictions were limited to HLA‐A and ‐B types present in \>5% of the population within Europe or North America [63](#ajt13598-bib-0063){ref-type="ref"}. For each HLA allele, the 20 epitopes within the BKPyV EVGR sequence displaying the best scores in both algorithms were considered.

BKPyV EVGR--derived peptides {#ajt13598-sec-0008}
----------------------------

A pool of 180 overlapping 15mP spanning BKPyV EVGR (Dunlop strain) or a pool of 11 longer LPm1‐11 peptides (long peptide pool \[LPP\]) covering immunodominant clusters of predicted BKPyV 9mer epitopes were used for *in vitro* T cell expansion. Cells were restimulated after expansion, as reported [35](#ajt13598-bib-0035){ref-type="ref"}, using 15mP or a pool of 73 predicted 9mer peptides (9mP). The 9mer peptides were also resuspended in different subpools according to a checkerboard matrix approach, from A to H and from 1 to 9 (called 9msA--H and 9ms1--9). Each of the 73 peptides was present in two subpools. An additional set of 24 9mer peptides that initially were not predicted by computer algorithms and three longer peptides were later synthesized and used to assess "prediction gaps" in EVGR sequence. All peptides were \>70% pure and resuspended in dimethyl sulfoxide (10 mg/mL; Eurogentec Deutschland GmbH, Köln, Germany).

In vitro expansion of T cells {#ajt13598-sec-0009}
-----------------------------

Freshly isolated or thawed PBMCs were stimulated with LPP or 15mP (200 ng/mL) in 24‐well plates and incubated for 7--14 days at 37°C in 5% CO~2~ before performing phenotypic and functional assays. Recombinant human IL‐2 (20 U/mL; Peprotech, Rocky Hill, NJ) and recombinant IL‐7 (5 ng/mL; Peprotech) were added once a week.

Enzyme‐linked immunospot assay {#ajt13598-sec-0010}
------------------------------

Enzyme‐linked immunospot (ELISpot) assay was performed, as described previously [35](#ajt13598-bib-0035){ref-type="ref"}. Expanded T cells were cultured without (negative control) or with BKPyV‐specific peptides. Cells treated with *Staphylococcus* enterotoxin B (2 μg/mL; Sigma‐Aldrich, St. Louis, MO) or phytohemagglutinin‐[l]{.smallcaps} (PHA; 2 μg/mL; Roche Diagnostics GmbH, Mannheim, Germany) were used as positive control. ELISpot data are averaged in duplicate or triplicate wells with background wells subtracted. Responses greater than background plus 2 standard deviations were considered positive.

MHC streptamer staining {#ajt13598-sec-0011}
-----------------------

BKPyV‐specific T cells were stained with phycoerythrin (PE)‐ or allophycocyanin‐labeled streptamers (IBA GmbH, Göttingen, Germany) composed of ≈8--12 peptide‐loaded MHC molecules, allowing better sensitivity than tetramers or pentamers. The cells were then incubated with CD8‐PE‐Cy7 antibody (BD Biosciences, San Jose, CA) and analyzed on a flow cytometer (FACSCanto; BD Biosciences) using FACSDiva software.

CFSE proliferation assay {#ajt13598-sec-0012}
------------------------

PBMCs were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE; eBioscience, Vienna, Austria) before being expanded with BKPyV‐derived peptides and analyzed by flow cytometry.

CD107a degranulation assay {#ajt13598-sec-0013}
--------------------------

Expanded T cells were rechallenged for 5 h with BKPyV 9mer peptides or phorbol 12‐myristate 13‐acetate (100 ng/mL; Sigma‐Aldrich) and ionomycin (1 µg/mL; Sigma‐Aldrich) as positive control in the presence of PE‐Cy7--labeled CD107a antibody (BD Biosciences) before being analyzed by flow cytometry.

Cytotoxicity assay {#ajt13598-sec-0014}
------------------

Expanded T cells were cocultured for 4 h with ^51^Cr‐labeled autologous PHA blasts pulsed with BKPyV 9mer peptide at different effector:target cell ratios. Counts per minute were taken with a β‐counter (TopCount; PerkinElmer, Waltham, MA).

Statistical analysis {#ajt13598-sec-0015}
--------------------

Proportions of viremic or viruric KTRs, and proportions of matched or mismatched patient populations were compared using the Fisher exact test with GraphPad Prism version 4.00 (GraphPad Software, La Jolla, CA). Differences corresponding to p \< 0.05 were considered statistically significant.

Additional material and methods can be found in the supporting information.

Results {#ajt13598-sec-0016}
=======

Bioinformatic prediction of HLA‐A-- and HLA‐B--binding BKPyV 9mer epitopes {#ajt13598-sec-0017}
--------------------------------------------------------------------------

Syfpeithi and IEBD programs were used to predict 20 top‐scoring 9mer epitopes encoded in the BKPyV EVGR for each of 14 HLA‐A and ‐B types prevalent in Europe and North America. These HLA types are common in many ethnics groups worldwide, as shown in Table S3. The predictions for each HLA type were visualized relative to the BKPyV EVGR sequence and arbitrarily numbered (Figure [1](#ajt13598-fig-0001){ref-type="fig"}). Although each HLA type appeared to have its own unique 9mer pattern, there were clearly sequence stretches in which the predicted epitopes appeared to cluster locally as well as across several HLA types by both algorithms (Figure [1](#ajt13598-fig-0001){ref-type="fig"}). To focus on immunodominant epitopes, a total of 73 predicted 9mer epitopes including epitopes identified in previous studies (Table S4) were selected from different prominent clusters present across most HLA‐A and ‐B types for chemical synthesis and experimental testing. Twenty‐four additional 9mer predictions outside of these clusters were synthesized, resulting in a total of 97 9mer‐epitope candidates. In addition, 11 longer peptide stretches were selected for domains in which several predicted 9mers overlapped.

![***In silico* prediction of BKPyV EVGR immunogenic epitopes**. The graph depicts 20 top‐scoring 9mer epitopes predicted in BKPyV EVGR sequences for common HLA‐A and ‐B types in Europe and North America, according to the Immune Epitope Database (X) and Syfpeithi (□) algorithms. BKPyV, BK polyomavirus; EVGR, early viral gene region.](AJT-16-1193-g001){#ajt13598-fig-0001}

Experimental testing of predicted BKPyV 9mer epitopes in HIs {#ajt13598-sec-0018}
------------------------------------------------------------

PBMCs were obtained from 42 HIs (median age 46 years) (Table S1) who were BKPyV‐IgG seropositive, as defined by the normalized OD~492nm~ of \>0.1 at 200‐fold dilution (Figure [2](#ajt13598-fig-0002){ref-type="fig"}), which was previously shown to be very highly sensitive and specific [58](#ajt13598-bib-0058){ref-type="ref"}. Because of the low BKPyV‐specific T cell frequency in PBMCs, an *in vitro* expansion protocol was adopted [35](#ajt13598-bib-0035){ref-type="ref"}, and PBMCs were stimulated using BKPyV EVGR 15mP or LPP. IFN‐γ ELISpot assays were performed before and after expansion using 15mP, LPP, 9mP and 9msP for single‐epitope cross‐identification.

![**BKPyV IgG serology of 42 healthy individual participants**. Normalized BKPyV IgG antibody levels are shown at 1:100, 1:200 and 1:400 dilutions (median, box shows 25th, 75th percentiles; whiskers 5% and 95%). Positive serological status was defined as OD~492nm~ ≥0.100 (dotted line) at the 1:200 dilution. BKPyV, BK polyomavirus; nOD, net optical density.](AJT-16-1193-g002){#ajt13598-fig-0002}

The approach is illustrated in HI‐29: PBMCs were either stimulated directly or after expansion using the indicated peptide pools (Figure [3](#ajt13598-fig-0003){ref-type="fig"}A). IFN‐γ ELISpot results showed that the *in vitro* T cell expansion protocol resulted in a significant increase of BKPyV‐specific T cells that responded to both 15mP and 9mP (Figure [3](#ajt13598-fig-0003){ref-type="fig"}A). Rechallenge with 9mer subpools showed that the highest responses could be attributed to specific subpools, namely, 9msA and 9ms4 (Figure [3](#ajt13598-fig-0003){ref-type="fig"}B). The single 9mer common to both of these subpools is 9m127. A slightly weaker response was also observed in 9ms5, suggesting some response to eight amino acid--overlapping 9m128 as well. Rechallenge of expanded cells with single 9mer‐peptides confirmed that the major response to 9msP was indeed attributable to 9m127, with a response similar to that observed with 9mP or 9msA and 9ms4 and, to a lesser extent, to 9m128 (Figure [3](#ajt13598-fig-0003){ref-type="fig"}C). Based on the peptide length of nine amino acids, this functional IFN‐γ response should originate from CD8^+^ T cells. To address this directly, expanded T cells were stained with HLA‐B\*07:02 9m127 streptamer and with CD8 surface marker and analyzed by flow cytometry (Figure [3](#ajt13598-fig-0003){ref-type="fig"}D). A population of HLA‐B\*0702--positive 9m127‐specific CD8^+^ T cells (right panel) could be detected, representing 3.9% of the total lymphocyte population.

![**Characterization BKPyV EVGR 9mer‐specific immune responses**. (A) Interferon γ enzyme‐linked immunospot assay using PBMCs directly after isolation from fresh blood (day −1; left panel) or after 9‐day expansion with BKPyV EVGR peptides (day +9; right panel). Cells were treated with medium (neg), SEB, 9mP, overlapping 15mP spanning the BKPyV EGFR sequence or with LPP. (B) Rechallenge of 9‐day expanded T cells with 9mer subpools 9msA to 9msH, and 9ms1 to 9ms9. Each peptide was present in two subpools for cross‐identification. (C) Identification of 9mer epitopes by restimulating expanded cell with single 9mer peptides contained in the subpools eliciting the highest responses (e.g. 9msA, 9ms4, 9ms5). (D) HLA streptamer staining using PE‐labeled Strep‐Tactin without (left panel) or with (right panel) HLA‐B\*0702 molecules bearing 9m127 peptide. (E) CD8^+^ T cell proliferation during *in vitro* expansion. PBMCs were stained at day 0 with CFSE dye (red) that dilutes on cell division (*x*‐axis). HLA‐B\*07--positive 9m127‐specific T cells are shown in blue. (F) Epitope‐specific degranulation of CD8^+^ T cells using PE‐Cy7‐labeled CD107a antibody (red) on 5‐h restimulation with 9m127 (right panel) or another BKPyV EVGR peptide (left panel). HLA‐B\*07 9m127‐specific T cells are shown in blue. (G) The 9mer‐specific cytotoxic activity of expanded T cells. Autologous phytohemagglutinin‐L blasts stained with ^51^Cr and pulsed with 9mP (▪) or 9m127 (▴) were used as target cells and incubated for 4 h with expanded T cells (effector cells). Percentage of target cells lysis (*y*‐axis) at the different effector:target cells ratios (*x*‐axis) is shown. 9mP, 9mer‐peptide pool; 15mP, 15mer peptide pool; BKPyV, BK polyomavirus; CFSE, carboxyfluorescein diacetate succinimidyl ester; EVGR, early viral gene region; LPP, long peptide pool; Neg, negative; PBMCs, peripheral blood mononuclear cells; PE, phycoerythrin; SEB, *Staphylococcus* enterotoxin B.](AJT-16-1193-g003){#ajt13598-fig-0003}

To address proliferation following peptide stimulation, PBMCs were stained with CFSE before expansion and labeled for CD8 and HLA‐B\*0702--positive 9m127 streptamer after expansion. CSFE dilution indicated the presence of at least nine divisions of the CD8^+^ T cell population (Figure [3](#ajt13598-fig-0003){ref-type="fig"}E, red population). Gating on CCR7 and CD45RA revealed that a majority of CD8^+^ T cells undergoing seven, eight and nine division were of central or effector memory phenotype, in contrast to naïve CD8^+^ T cells that did not divide or that divided only once (Figure S1). HLA‐B\*0702--positive 9m127‐specific CD8^+^ T cells showed the lowest CSFE signals, indicating that these cells had divided close to once per 1--2 days during the expansion period (Figure [3](#ajt13598-fig-0003){ref-type="fig"}E, blue population).

To correlate HLA‐B\*0702--positive 9m127‐specific CD8^+^ T cells and degranulation function, expanded T cells were stimulated with 9m127 or another BKPyV peptide (9m259) for 5 h in the presence of CD107a antibody and stained for HLA‐B\*0702--positive 9m127 streptamers (Figure [3](#ajt13598-fig-0003){ref-type="fig"}F). Only 9m127 induced degranulation of nearly the entire HLA‐B\*0702--positive 9m127 CD8^+^ T cell population.

T cell functionality was also investigated in a killing assay in which lytic activity of expanded T cells against autologous ^51^Cr‐labeled PHA blasts pulsed with the single 9m127 or with 9mP was assessed (Figure [3](#ajt13598-fig-0003){ref-type="fig"}G). The results showed that 9m127 mediates a mean specific lysis of 48% at an effector:target ratio of 20:1. This single 9m127 response was comparable to that mediated by 9mP, in line with an immunodominant BKPyV epitope.

This experimental approach permitted functional identification of candidate 9mer epitopes from BKPyV recognized by CD8^+^ T cells in strongly BKPyV‐seropositive HIs, even if cells were present at a low frequency among PBMCs. In some cases, the responses induced by 15mP and by 9mP did not correlate (data not shown), suggesting the presence of different epitope‐specific T cell populations among CD4^+^ or CD8^+^ subsets. Testing of expanded PBMCs from BKPyV‐ and JC polyomavirus (JCPyV)--seronegative HIs remained negative for 9mer responses but showed some residual 15mer responses (Figure S2, left panel). This indicated that this *in vitro* protocol of only 2 weeks expansion did not lead to significant priming of naïve CD8^+^ T cells, as detected by 9mer responses, but most likely induced proliferation of memory CD8^+^ T cells. Interestingly, HIs who were seronegative for BKPyV but seropositive for JCPyV showed a response to BKPyV EVGR 15mer and 9mer (Figure S2, right panel). This suggested the presence of LTag crossreactive responses from JCPyV‐specific T cells, as discussed previously [35](#ajt13598-bib-0035){ref-type="ref"}.

In total, 42 HIs were analyzed, and the frequency of responses was summarized according HLA type in a heat map (Table [1](#ajt13598-tbl-0001){ref-type="table-wrap"}). Only two 9mer responses had frequencies of \<15% of HIs (9m316, 9m518). Many 9mer‐epitope responses could be detected in up to one‐third of HIs, but some epitopes had more frequent responses (40 epitopes elicited IFN‐γ production in 30--49% of donors; 17 epitopes induced IFN‐γ ELISpot responses in \>50% of tested participants). The presence of response hotspots supports the notion that not all 9mer epitopes are equally potent, and certain clustering is observed. This is illustrated by the ELISpot results for selected epitopes (Figure [4](#ajt13598-fig-0004){ref-type="fig"}). The overall results indicated that BKPyV EVGR‐specific 9mer T cell responses were heterogeneous in terms of frequency and strength. For some HLA types, positive responses were found more frequently and directed towards more epitopes compared to HLA types. For example, in participants positive for HLA‐A\*03, ‐A\*11, ‐B\*07, ‐B\*35, ‐B\*39, ‐B\*44 or ‐B\*51, more than one epitope could be identified in ≥50% of HIs (Table [1](#ajt13598-tbl-0001){ref-type="table-wrap"}). Single 9mer epitopes were associated with variable responses in HIs (Figure [4](#ajt13598-fig-0004){ref-type="fig"}), whereby values of \>69 spot‐forming units (SFU)/10^6^ cells were regarded as strong responses in accordance with a previously defined threshold of protection from BKPyV viremia in KTRs [35](#ajt13598-bib-0035){ref-type="ref"}.

###### 

BKPyV EVGR 9mer responses in IFN‐γ ELISpot assay

![](AJT-16-1193-g006){#nlm-graphic-7}
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![**Breadth and strength of BKPyV EVGR epitope‐specific immune responses in HIs**. The 9mer‐epitope responses in interferon γ enzyme‐linked immunospot assay (dots) found in at least 40% of HIs, listed in Table [1](#ajt13598-tbl-0001){ref-type="table-wrap"}, with positive streptamer staining or previous publication (median in red, box 25th and 75th percentiles, whiskers 5th and 95th). BKPyV, BK polyomavirus; HI, healthy individual; na, not available; SFU, spot‐forming unit.](AJT-16-1193-g004){#ajt13598-fig-0004}

In summary, 9m301 elicited specific responses in 47% of participants with HLA‐B\*07 with a median of 292 SFU/10^6^ cells. The same 9mer epitope was found to be immunogenic in 35% of donors with HLA‐A\*02 and 45% with HLA‐A\*24. In addition, 9m327 induced a median response of 304 SFU/10^6^ cells in eight HIs who were positive for HLA‐A\*03. Overall, 9m330 induced fairly strong responses in 53% of HIs who were positive for HLA‐A\*03, with a median of 593 SFU/10^6^ cells. Moreover, 9m330‐specific IFN‐γ production could also be detected in some HIs with HLA‐B\*07 and ‐B\*39. Finally, 9m389 elicited a median response of 299 SFU/10^6^ cells in six participants with HLA‐A\*02 (35%) and elicited IFN‐γ production in 50% of participants with HLA‐A\*11 and 18% with HLA‐A\*24 (Table [1](#ajt13598-tbl-0001){ref-type="table-wrap"}).

In line with the predicted clusters, some areas in the EVGR appeared to be more immunogenic than others (Table [1](#ajt13598-tbl-0001){ref-type="table-wrap"}). The domain spanning from 9m383 to 9m393 could induce frequent responses in participants with HLA‐A\*02, ‐A\*11, ‐B\*35 and ‐B\*39. The domain from 9m119 to 9m133 appeared to be highly immunogenic across different HLA types. Additional epitope clusters in the 221--240 and 536--645 EVGR areas also appeared to be more immunogenic (Table S5); however, they were tested in only few participants and thus deserve further investigation.

HLA restriction of BKPyV EVGR‐specific T cell responses in HIs {#ajt13598-sec-0019}
--------------------------------------------------------------

To address HLA specificity of IFN‐γ--inducing 9mer epitopes, cells were stained with MHC streptamers (Table [2](#ajt13598-tbl-0002){ref-type="table-wrap"}). Some MHC streptamers showed strong staining such as HLA‐B\*07-- and ‐B\*08--positive 9m127 streptamers that were identified in 89% and 67% HIs with mean values of 0.86% and 0.27%, respectively. T cells presenting 9m127 via the HLA‐A\*02 molecule could not be detected, despite high 9m127‐specific IFN‐γ T cell responses among HLA‐A\*02--positive HIs (Figure [4](#ajt13598-fig-0004){ref-type="fig"}A), suggesting that those responses were not HLA‐A\*02 restricted. Conversely, HLA‐A\*02--positive T cells specific for 9m679 could be detected in 50% of tested participants with HLA‐A\*02, despite a low number of responsive donors in the IFN‐γ ELISpot assay (18%).

###### 

HLA‐A and ‐B specificity of BKPyV EVGR CD8^+^ T cell responses in HIs

  HLA type   Streptamer   Tested HIs (n)   HIs with positive response (%)   Epitope‐specific CD8^+^ cells T cells (mean %)
  ---------- ------------ ---------------- -------------------------------- ------------------------------------------------
  A\*02      316          6                33                               0.04
             679          6                50                               0.04
  A\*03      327          5                40                               0.01
  A\*24      265          4                25                               0.02
             312          4                25                               0.02
             342          7                14                               0.04
             389          7                14                               0.02
  B\*07      127          9                89                               0.86
             301          1                100                              0.23
  B\*08      127          3                67                               0.27
  B\*35      121          1                100                              0.03
             240          3                67                               0.16
             391          4                50                               0.03
  B\*39      121          2                50                               0.19
             240          2                50                               0.04
  B\*40      119          2                50                               0.3
             330          1                100                              0.25
             631          1                100                              0.17

BKPyV, BK polyomavirus; EVGR, early viral gene region; HI, healthy individual.

John Wiley & Sons, Ltd

Of note, HLA‐A\*03--positive 9m327‐specific T cells could be detected in 40% of HIs with HLA‐A\*03, but 9m327 elicited IFN‐γ responses in donors with HLA‐A\*03, ‐A\*11 and ‐B\*07. HLA‐A\*24--positive 9m389‐specific T cells could be detected in 14% of HIs, but 9m389 elicited IFN‐γ responses in donors with HLA‐A\*02, ‐A\*11 and ‐A\*24. HLA‐B\*07--positive 9m301‐specific T cells could be detected in the only tested participants with HLA‐B\*07, but 9m301 elicited IFN‐γ responses in donors with HLA‐A\*02, ‐\*A24 and ‐B\*07. Finally, HLA‐B\*40--positive 9m119‐specific T cells could be detected in 50% of HIs with HLA‐B\*40 but 9m119 elicited IFN‐γ responses in donors wit HLA‐B\*07, ‐B\*40 and ‐B\*44.

Finally, some T cell--activating 9mers were presented by more than one HLA molecule, namely, 9m121 (HLA‐B\*35 and ‐B\*39), 9m127 (HLA‐B\*07 and ‐B\*08), and 9m240 (HLA‐B\*35 and ‐B\*39) (Table [2](#ajt13598-tbl-0002){ref-type="table-wrap"}).

BKPyV EVGR‐specific epitope CD8^+^ T cell responses in pediatric KTRs {#ajt13598-sec-0020}
---------------------------------------------------------------------

To extend the results from HIs to the clinical setting, BKPyV‐specific T cell responses were investigated in 19 pediatric KTRs who were protected or recovered from BKPyV viremia (Table S2). Several epitopes identified in HIs could be confirmed in these 19 KTRs (Table [3](#ajt13598-tbl-0003){ref-type="table-wrap"}).

###### 

BKPyV EVGR‐specific T cell responses in kidney transplant recipients

                IFN‐γ ELISpot   MHC‐streptamers                    
  ------- ----- --------------- ----------------- ----- ---- ----- ------
  A\*01   256   2               50                100   --   --    --
          327   2               100               40    3    67    0.10
          386   --              --                --    3    33    0.02
  A\*02   316   --              --                --    5    20    0.14
          302   8               12                245   --   --    --
          389   9               67                312   --   --    --
          391   4               25                840   --   --    --
          393   --              --                --    3    33    0.06
          510   10              50                95    --   --    --
          536   --              --                --    4    25    0.14
          679   9               89                324   11   36    0.09
  A\*03   256   3               30                120   --   --    --
          272   --              --                --    3    67    0.12
          327   3               30                270   1    100   0.05
  A\*11   256   3               30                120   --   --    --
          276   3               30                465   --   --    --
          327   3               67                270   3    33    0.08
          389   3               33                70    --   --    --
  A\*24   127   3               33                200   --   --    --
          342   --              --                --    1    100   0.08
          389   4               50                370   2    50    0.02
  B\*07   119   2               50                130   2    50    0.07
          127   2               100               280   2    50    0.08
          240   --              --                --    1    100   0.03
          301   --              --                --    1    100   0.09
          389   2               50                285   --   --    --
  B\*08   127   1               100               150   --   --    --
          462   --              --                --    1    100   0.08
          679   --              --                --    1    100   0.07
  B\*35   240   5               80                410   --   --    --
          391   5               40                590   --   --    --
          633   5               40                145   --   --    --
  B\*51   256   4               25                180   --   --    --
          389   5               40                135   2    50    0.10
          506   2               100               175   --   --    --

BKPyV, BK polyomavirus; EVGR, early viral gene region; IFN‐γ, interferon γ; KTR, kidney transplant recipient; SFU, spot‐forming unit.

John Wiley & Sons, Ltd

Overall, 9m389 was recognized in 67% of patients with HLA‐A\*02, with a mean value of 312 SFU/10^6^ cells, but HLA‐A\*02 restriction could not be confirmed. This epitope induced T cell responses in 33%, 50%, 50%, and 40% of patients with HLA‐A\*11, ‐A\*24, ‐B\*07, and ‐B\*51, respectively, with HLA specificity confirmed for HLA‐A\*24 and ‐B\*51 molecules. In addition, 9m679 was found to be immunogenic in eight of nine tested patients with HLA‐A\*02, and specific CD8^+^ T cells were detectable in 36% of patients with HLA‐A\*02. ELISpot assays could confirm 9m327 and MHC streptamer staining in KTRs who were positive for HLA‐A\*01, ‐A\*03, and ‐A\*11. Furthermore, 9m127 elicited T cell responses in 100% of patients with HLA‐B\*07 and ‐B\*08, and MHC streptamer staining identified CD8^+^ T cells for one patient with HLA‐B\*07.

Four 9mer epitopes elicited functional IFN‐γ responses in HIs and KTRs and were HLA‐specific in both cohorts: 9m127 (HLA‐B\*07 specific), 9m327 (HLA‐A\*03 specific), 9m389 (HLA‐A\*24 specific) and 9m679 (HLA‐A\*02 specific). Three 9mer responses were found in KTRs but not in HIs (9m302, 9m536, and 9m633).

BKPyV replication prevalence in pediatric KTRs {#ajt13598-sec-0021}
----------------------------------------------

To evaluate the potential association of BKPyV replication with specific HLA‐A and ‐B types, a prospective cohort of 118 consecutive pediatric KTRs was analyzed, of whom 38 (32%) experienced BKPyV viremia. The rate of BKPyV viremia was not equally distributed across HLA types or mismatches (Figure [5](#ajt13598-fig-0005){ref-type="fig"}). Although the overall sample size was too small for statistically supported conclusions, patients with HLA‐A\*01 seemed to have lower rates of viremia compared with the overall population (p \< 0.05), and mismatching for this allele was present in about half of the KTRs. Similarly, a trend for a lower rate of BKPyV viremia was seen among patients positive for HLA‐A\*26, ‐A\*28 and ‐B\*57, without a clear association with matching. Interestingly, 60% of nonviremic patients with HLA‐B\*07 were matched for this particular allele, whereas all viremic patients with HLA‐B\*07 were mismatched (Figure [5](#ajt13598-fig-0005){ref-type="fig"}). This observation would be in line with the hypothesis that the absence of HLA‐B\*07 might increase the risk of viremia if confirmed by an independent study of larger sample size. In contrast, there was a higher proportion of HLA‐B\*35--matched patients among viremic KTRs than among the nonviremic KTRs (p \< 0.05). Finally, viremia seemed to be independent of matching for HLA‐A\*01, ‐A\*24, ‐A\*29, ‐B\*08, and ‐B\*51 types, for which the proportions of matched patients among viremic and nonviremic patients were similar (Figure [5](#ajt13598-fig-0005){ref-type="fig"}). A higher rate of high‐level viruria was found in patients with HLA‐A\*31 (p \< 0.05), whereas a trend toward a lower rate was found in patients with HLA‐B\*57 (p \< 0.05) and HLA‐A\*01 (p = 0.08) (data not shown). Consequently, although immunogenic properties of some 9mer epitopes could be confirmed in KTRs, a simple association of single mismatching with risk or matching with protection could not be derived from this pediatric cohort.

![**BKPyV viremia and HLA‐matching in 118 pediatric KTRs**. The percentages of viremic (left side) and nonviremic (right side) KTRs according to HLA type are shown. For each HLA type, the percentage of patients displaying matched (light gray) or mismatched (dark gray) allele with their kidney donor is shown. The number of KTRs with the most common HLA types is indicated at left. BKPyV viremia was analyzed for single HLA types versus the whole population (p‐value for HLA type) or by comparing viremia occurrence in matched and mismatched patients (p‐value for HLA matching; Fisher exact test). BKPyV, BK polyomavirus; KTR, kidney transplant recipient.](AJT-16-1193-g005){#ajt13598-fig-0005}

Discussion {#ajt13598-sec-0022}
==========

BKPyV‐associated nephropathy is now widely recognized as an emerging complication in KT [64](#ajt13598-bib-0064){ref-type="ref"}, [65](#ajt13598-bib-0065){ref-type="ref"}, [66](#ajt13598-bib-0066){ref-type="ref"}, [67](#ajt13598-bib-0067){ref-type="ref"}. Insufficient BKPyV‐specific T cell control of the recipient over viral replication in donor allograft is suspected as the common denominator and key mechanism [67](#ajt13598-bib-0067){ref-type="ref"}. Independent single‐center studies indicated that reducing immunosuppression was associated with increasing BKPyV‐specific T cell responses and coincided with clearance of viremia and nephropathy [30](#ajt13598-bib-0030){ref-type="ref"}, [34](#ajt13598-bib-0034){ref-type="ref"}, [35](#ajt13598-bib-0035){ref-type="ref"}, [36](#ajt13598-bib-0036){ref-type="ref"}. Alternatively, the decline of cellular immunity at 1 month after transplantation has been proposed to identify patients at increased risk of BKPyV viremia, but no or low IFN‐γ responses in at least half of patients impeded the predictive value for individual patients [53](#ajt13598-bib-0053){ref-type="ref"}. Given these experiences and the fact that mostly CD4^+^ T cell responses were measured by overlapping 15mP, better characterization of BKPyV epitope‐specific CD8^+^ T cell response seems needed to improve the current understanding and clinical utility of BKPyV‐specific cellular immunity. Because we observed that BKPyV‐specific CD8^+^ T cell responses are more frequently directed to LTag than VP1 [30](#ajt13598-bib-0030){ref-type="ref"}, [35](#ajt13598-bib-0035){ref-type="ref"}, we focused on the BKPyV EVGR--encoded epitopes rather than the capsid antigens [68](#ajt13598-bib-0068){ref-type="ref"}, [69](#ajt13598-bib-0069){ref-type="ref"}. The following aspects emerged from the present study.

First, systematic *in silico* analysis of immunogenic epitopes predicts both immunogenic hotspot clusters and gaps in BKPyV EVGR for each of the 14 major HLA class I types. Predicted areas were similarly clustered across different HLA class I types, and this observation argues for potential immunodominant domains, in which the virus would be particularly susceptible to immune control and selection pressure. Because these domains are present in EVGR‐encoding crucial viral regulatory proteins early in the viral replication cycle, at least transient escape from cellular immune control would be particularly important for BKPyV replication [70](#ajt13598-bib-0070){ref-type="ref"}, [71](#ajt13598-bib-0071){ref-type="ref"}.

Second, the expansion protocol used in the present study has been devised to overcome the low frequency of BKPyV‐specific T cell responses to overlapping 15mP [35](#ajt13598-bib-0035){ref-type="ref"} and was used successfully in the prospective study of pediatric KTRs [30](#ajt13598-bib-0030){ref-type="ref"}. Our results demonstrate that functional CD8^+^ T cell responses can be amplified which selectively target few 9mer epitopes located in predicted immunodominant clusters. CFSE dye dilution and streptamer staining supported this central observation, indicating that these cells were among the most active, dividing approximately once every 1--2 days. The 9mer responses were functionally defined by IFN‐γ secretion but could be linked in principle to 9mer‐specific cell surface expression of CD107a, a marker of granzyme and perforin degranulation, and to cytotoxic activity in ^51^Cr release assays.

Third, although certain 9mer epitopes were shown to be selective for specific HLA types by streptamer staining of CD8^+^ T cells, presentation by different HLA class I types could be observed. This has been demonstrated for HLA types that belong to crossreacting group 1C (e.g. HLA‐A\*01, ‐A\*03 and ‐A\*11) or 7C (e.g. HLA‐B\*07 and ‐B\*08) [72](#ajt13598-bib-0072){ref-type="ref"}.

Fourth, 10 of the 9mer epitopes identified in HIs could be confirmed in an unrelated cohort of 19 pediatric KTRs who were protected or recovering from BKPyV replication. Consequently, predicted and tested immunodominant responses could be linked to the clinically relevant situation of immunosuppressed KTRs.

Interestingly, three additional 9mer responses found in KTRs had been predicted but were not detected in HIs. This might indicate that responses in HIs may be lower and hence less detectable. Conversely, the additional responses in pediatric KTRs might result from extensive exposure to BKPyV replication and the more vigorous immune response described for children [5](#ajt13598-bib-0005){ref-type="ref"}.

The fact that the major site of BKPyV replication is in donor cells of the renal allograft deserves consideration because this might affect HLA presentation and modify T cell receptor recognition of BKPyV epitopes. Interestingly, in our prospective cohort of 118 pediatric KTRs, single HLA mismatching could not be associated with BKPyV viremia. Although sample size might be an important aspect [73](#ajt13598-bib-0073){ref-type="ref"}, it could also reflect the fact that other risk factors besides HLA‐mismatching including maintenance immunosuppression can promote progression to viremia and nephropathy equally well and thereby contribute to the failing balance between BKPyV replication in the graft and BKPyV‐specific T cell control in an individual patient.

Previous studies focused mainly on persons with HLA‐A\*02 [41](#ajt13598-bib-0041){ref-type="ref"}, [51](#ajt13598-bib-0051){ref-type="ref"}, [55](#ajt13598-bib-0055){ref-type="ref"}, [71](#ajt13598-bib-0071){ref-type="ref"} and more rarely on epitopes restricted for HLA‐A\*01, ‐A\*03, ‐A\*11, ‐B\*07 and ‐B\*08 [54](#ajt13598-bib-0054){ref-type="ref"}, [56](#ajt13598-bib-0056){ref-type="ref"}, [74](#ajt13598-bib-0074){ref-type="ref"}. Most published epitopes could be confirmed in our study, such as the HLA‐A\*02--restricted epitopes 9m679 and 9m316 or the HLA‐B\*07-- and HLA‐B\*08--restricted 9m127, validating our approach and underscoring their potential immunodominance. Our approach expands this list to at least 39 mostly new 9mer epitopes, of which 21 were linked by streptamer staining to a range of HLA types. These findings may be of high interest, especially because BKPyV epitope‐specific T cells could be sorted using specific MHC streptamers, further expanded *in vitro* after removal of the MHC‐streptamer complex and used for adoptive T cell transfer. In addition, some of the epitopes identified in the present study have common sequences with the closely related JCPyV, suggesting that BKPyV‐specific T cells might induce cross‐protection to JCPyV, which is also associated with disease in some immunocompromised patients.

Our study has several limitations that should be considered for a balanced interpretation of the results. First, not all IFN‐γ responses could be linked unambiguously to HLA types present in functionally responding HIs or KTRs by streptamers. There may be several reasons for this, including low T cell frequencies, technical properties of certain streptamers that reduce sensitivity, or the fact that some 9mer epitopes eliciting IFN‐γ responses were presented by HLA molecules not predicted in this study, especially in the transplantation context. These aspects might be better addressed as prediction and technology improves. Second, some aspects of BKPyV‐specific CD8^+^ T cell characterization (proliferation during expansion, cytotoxicity, degranulation) could not be performed for all epitopes but could be addressed at least in principle in experimental animal models [75](#ajt13598-bib-0075){ref-type="ref"}, [76](#ajt13598-bib-0076){ref-type="ref"}. Third, the use of cryopreserved samples instead of fresh PBMCs might have reduced detection of some rare BKPyV‐specific T cells, even if immunodominant responses were still detectable. Fourth, the investigation of cellular immune responses in KTRs was done in a relatively small cohort; therefore, the number of identified epitopes was limited. Overall, the results are encouraging to take this approach to larger clinical cohorts and relevant prospective study settings.

We conclude that *in vitro* cellular expansion using 15mP EVGR peptides or longer peptides allowed us to experimentally test the immunogenicity of 9mer epitopes predicted by *in silico* algorithms. We could identify immunogenic 9mer epitopes in both HIs and KTRs and extended the current list to at least 39. Several epitopes were located in clusters and induced specific responses in different common HLA class I types, as expected for immunodominant epitopes. Further studies will have to prove how this information can be best harnessed for clinically relevant immune monitoring and possibly foster adoptive T cell transfer for prophylaxis and therapy in kidney and hematopoietic stem cell transplant patients.
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###### 

**Figure S1: Phenotype of dividing cells during *in vitro* expansion**. Peripheral blood mononuclear cells from a healthy donor were labeled with CFSE before being expanded *in vitro* and stained with CD45RA and CCR7 markers. (A) CFSE content of CD8^+^ T cells after *in vitro* expansion. Gates P11--P20 allow discrimination of different CD8^+^ T cell divisions (P11 = no division; P12 = one division; P13 = two divisions, and so forth). (B) CD45RA and CCR7 expression by CD8^+^ T cells at different division stages. Each panel is gated in one of the 10 gates (P11--P20). CFSE, carboxyfluorescein diacetate succinimidyl ester.
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**Figure S2: Immune responses of BKPyV‐seronegative HIs**. PBMCs from HIs who were seronegative for both BKPyV and JCPyV (HI‐43, HI‐44, HI‐45 and HI‐46; left panel) or seropositive for JCPyV and seronegative for BKPyV (HI‐47, HI‐48; normalized enzyme‐linked immunosorbent assay net OD (58)) (right panel) were expanded for 14 days in the presence of BKPyV 15mP and restimulated with BKPyV 15mP, LPP or 9mP in interferon γ enzyme‐linked immunospot assay. 9mP, 9mer‐peptide pool; 15mP, 15mer peptide pool; BKPyV, BK polyomavirus; HI, healthy individual participant; JCPyV, JC polyomavirus; LPP, long peptide pool; OD, optical density; SFU, spot‐forming unit.
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**Table S1:** Characteristics of 42 healthy individuals.
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**Table S2:** Characteristics of 19 pediatric kidney transplant recipients.
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**Table S3:** HLA allele frequencies in worldwide populations.
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**Table S4:** Previously published BKPyV EVGR 9mer epitopes predicted in our study.
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**Table S5:** BKPyV 9mer responses in IFN‐γ ELISpot assay ‐ additional 24 epitopes.
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